Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Depression drug Spravato wins European panel vote

Johnson & Johnson’s Spravato, a nasal spray for depression and potential blockbuster medicine, won recommendation for approval from a European Medicines Agency panel.

Read More »

Pear Therapeutics Announces FDA Submission for Somryst

Pear Therapeutics announced the filing of a submission to the U.S. Food and Drug Administration seeking marketing authorization for Somryst, a prescription digital therapeutic (PDT) intended for use in the treatment of adults with chronic insomnia and depression.

Read More »

Medication-free treatment for depression launches in the UK

Flow, a medical device company, launched a medication-free treatment for depression comprising a brain stimulation headset and therapy app.

Read More »

Vraylar wins U.S. FDA approval for bipolar depression

Allergan Plc’s Vraylar won U.S. regulatory approval to treat depressive episodes of bipolar I disorder, expanding the scope of treatment to a full spectrum of symptoms related to the condition.

Read More »

VistaGen’s Antidepressant Fails in Difficult-to-Treat Patients Trial

When major depressive disorder does not respond to at least two different types of antidepressant treatments in a moderate-to-severe depressive episode, it’s reclassified as treatment-resistant depression (TRD). South San Francisco-based VistaGen Therapeutics’ AV-101 failed to meet the primary efficacy endpoints for TRD in a Phase II clinical trial.

Read More »

Health apps may not disclose sharing your personal information

While nine out of 10 phone apps for depression and smoking cessation assessed in a recent study were found to be sharing user data with third parties, only two out of three disclosed they were doing so.

Read More »

Ketamine Appears to Repair Damaged Brain Circuits to Relieve Depression in Mice Study

A recent study showed that ketamine can possibly provide hours of relief for depression patients.

Read More »

Sage Wins FDA Approval for ‘Game-Changing’ Postpartum Depression Treatment

Sage Therapeutics shares were up after the company won approval for the postpartum depression treatment Zulresso (brexanalone).

Read More »

Aptar Pharma’s Bidose Nasal Drug Delivery Device Approved by U.S. FDA for Breakthrough Treatment of Depression

Aptar Pharma, a leading drug delivery systems provider, announced that the company’s Bidose nasal spray device was approved by the U.S. FDA for a breakthrough therapy in the field of depression.

Read More »

Indiana University Researchers Develop Blood Test for PTSD

Researchers at Indiana University developed a blood test that could help more accurately diagnose post-traumatic stress disorder.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

October 2019 Focus: Top 50 Company Profiles & Financials, Outcomes Creativity Index, and more!


Ad Right Bottom